Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hillman's experimental CorBec

The virtual venture-backed company, built from Day One with a merger end point in mind, is starting to pop up here and there as a strategic option.

The latest is a Hillman Medical Ventures startup, CorBec Pharmaceuticals Inc. CorBec (Horsham, Penn.) is focusing on manipulating macrophage function using small molecule steroid analogs to treat autoimmune disorders, infections associated with lung and kidney disease, atherosclerosis, and asthma and allergic disorders.


Read the full 680 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers